Other solutions provided to the hospital by Philips include Philips' Digital Ingenia 3.0T MRI with High-Intensity Focused Ultrasound (MR-HIFU), and advanced CT technology with high resolution and low-dose scanning. The MR-HIFU solution at Hong Duc General Hospital II will provide a non-invasive alternative to the traditional surgical treatment of uterine fibroids and enable non-invasive palliative pain treatment for bone metastases.
For further information, please contact:
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
About Hong Duc General Hospital
Established in September 2000, Hong Duc General Hospital is one of the most trusted healthcare providers in Ho Chi Minh City with hundreds of thousands of admissions annually. It has more than 5,000 inpatients and performs 2,000 laparoscopies per year. The hospital has gained many achievements in terms of patient outcome, investment in advanced healthcare equipment, and lower costs. The establishment of Hong Duc II and III Hospital aims at meeting social demands in healthcare service. For more information, please visit www.hongduchospital.vn
Back to HCB News
